title: Transforming growth factor beta in pancreatic cancer.
abstract: Pancreatic cancer has high incidence and mortality rates, and effective treatment remains a clinical challenge. As deregulation of the cytokine transforming growth factor beta (TGF-β) contributes to the progression of pancreatic carcinoma, the TGF-β pathway has been targeted using various strategies, including small molecule inhibitors of TGF-βRI, TGF-β-specific neutralizing antibodies and antisense compounds. As increased TGF-β2 levels in serum or tumor tissue of patients with pancreatic cancer correlated with poor prognosis, inhibition of TGF-β2 synthesis via the antisense oligonucleotide trabedersen (AP 12009) is a promising approach.
authors: Universitätsklinikum Münster, Hämotology & Onkologie, Münster, Albert-Schweitzer-Str. 33, Germany. andreas.hilbig@ukmuenster.de
authors: Andreas
authors: A
authors: Hilbig
authors: Helmut
authors: H
authors: Oettle